MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/jth.15878

Медицинская библиотека · Journal of thrombosis and haemostasis : JTH · 2022

Time between inhibitor detection and start of immune tolerance induction: Association with outcome in the BrazIT study.

Camelo Ricardo Mesquita, Dias Maíse Moreira, Caram-Deelder Camila, Gouw Samantha, de Magalhães Laura Peixoto, Zuccherato Luciana Werneck, Jardim Letícia Lemos, de Oliveira Andrea Gonçalves, de Albuquerque Ribeiro Rosângela, Franco Vivian Karla Brognoli, do Rosário Ferraz Roberti Maria, de Araújo Callado Fábia Michelle Rodrigues, Etto Leina Yukari, de Cerqueira Maria Aline Ferreira, Cerqueira Mônica Hermida, Lorenzato Cláudia Santos, de Souza Ieda Solange, Serafim Édvis Santos Soares, Garcia Andrea Aparecida, Anegawa Tânia Hissa, Neves Daniele Campos Fontes, Tan Doralice Marvulle, van der Bom Johanna, Rezende Suely Meireles, Brazilian Immune Tolerance (BrazIT) Study group

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Immune tolerance induction (ITI) is the treatment of choice for eradication of anti-factor VIII (FVIII) neutralizing alloantibodies (inhibitors) in people with inherited hemophilia A and high-responding inhibitor (PwHA-HRi). The association between ITI outcome and time elapsed between inhibitor detection and start of ITI (∆tinhi-ITI ) is debatable.

OBJECTIVE

The aim of this study was to evaluate this association among a large cohort of severe PwHA-HRi.

METHODS

Severe (factor VIII activity level <1%) PwHA-HRi on ITI (n = 142) were enrolled in 15 hemophilia treatment centers. PwHA-HRi were treated according to the Brazilian ITI Protocol. ITI outcomes were defined as success (i.e., recovered responsiveness to exogenous FVIII) and failure (i.e., no responsiveness to exogenous FVIII and requirement of bypassing agents to control bleeding).

RESULTS

Median ages at inhibitor detection and at ITI start were 3.2 years (interquartile range [IQR], 1.6-8.1) and 6.9 years [IQR, 2.6-20.1), respectively. PwHA-HRi were stratified according to ∆tinhi-ITI quartiles: first (0.0-0.6 year), second (>0.6-1.7 year), third (>1.7-9.2 years), and fourth quartile (>9.2-24.5 years). The overall success rate was 65.5% (93/142), with no difference among first, second, third, and fourth quartiles (62.9%, 69.4%, 58.3%, and 71.4%, respectively) even after adjusting the analyses for potential confounders.

CONCLUSION

In conclusion, delayed ITI start is not associated with failure of ITI in PwHA-HRi. Therefore, ITI should be offered for these patients, regardless of the time elapsed between the detection of inhibitor and the ITI start.

Для цитирования: Camelo Ricardo Mesquita, Dias Maíse Moreira, Caram-Deelder Camila, Gouw Samantha, de Magalhães Laura Peixoto, Zuccherato Luciana Werneck, Jardim Letícia Lemos, de Oliveira Andrea Gonçalves, de Albuquerque Ribeiro Rosângela, Franco Vivian Karla Brognoli, do Rosário Ferraz Roberti Maria, de Araújo Callado Fábia Michelle Rodrigues, Etto Leina Yukari, de Cerqueira Maria Aline Ferreira, Cerqueira Mônica Hermida, Lorenzato Cláudia Santos, de Souza Ieda Solange, Serafim Édvis Santos Soares, Garcia Andrea Aparecida, Anegawa Tânia Hissa, Neves Daniele Campos Fontes, Tan Doralice Marvulle, van der Bom Johanna, Rezende Suely Meireles, Brazilian Immune Tolerance (BrazIT) Study group. Time between inhibitor detection and start of immune tolerance induction: Association with outcome in the BrazIT study.. Journal of thrombosis and haemostasis : JTH. 2022. DOI: 10.1111/jth.15878.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.